Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OKSANA ANATOLIA SHLOBIN

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1780610840
CMS profile
217147
Location
FALLS CHURCH, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$57,681.66

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OKSANA ANATOLIA SHLOBIN

NPI 1780610840 · CMS profile ID 217147

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

FALLS CHURCH, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780610840?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OKSANA ANATOLIA SHLOBIN, NPI 1780610840, CMS profile ID 217147. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780610840?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). OKSANA ANATOLIA SHLOBIN, NPI 1780610840, CMS profile ID 217147. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780610840?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
OKSANA ANATOLIA SHLOBIN, NPI 1780610840, CMS profile ID 217147, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 101 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1780610840?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $57,681.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $2.7006/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050946025 CMS
United Therapeutics Corporation $105.3006/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050967493 CMS
United Therapeutics Corporation $9,000.0006/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050972089 CMS
Sumitomo Pharma America, Inc. $2,000.0005/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762933 CMS
Sumitomo Pharma America, Inc. $2,308.7605/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762937 CMS
Sumitomo Pharma America, Inc. $58.7605/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762941 CMS
United Therapeutics Corporation $4,800.0005/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050971857 CMS
Sumitomo Pharma America, Inc. $192.0005/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762917 CMS
Sumitomo Pharma America, Inc. $485.8305/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762921 CMS
Sumitomo Pharma America, Inc. $27.7705/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762925 CMS
Sumitomo Pharma America, Inc. $60.1805/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030762929 CMS
United Therapeutics Corporation $48.6805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964753 CMS
Bayer Healthcare Pharmaceuticals Inc. $24.3205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000431024 CMS
United Therapeutics Corporation $0.9105/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050945897 CMS
United Therapeutics Corporation $25.7005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050960091 CMS
United Therapeutics Corporation $23.2105/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050957173 CMS
United Therapeutics Corporation $23.2105/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050957175 CMS
United Therapeutics Corporation $43.8405/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050964579 CMS
United Therapeutics Corporation $52.8705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050965163 CMS
United Therapeutics Corporation $75.5105/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050966027 CMS
United Therapeutics Corporation $79.1105/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050966195 CMS
United Therapeutics Corporation $315.2705/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970229 CMS
Actelion Pharmaceuticals US, Inc. $21.8005/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772163 CMS
United Therapeutics Corporation $18.2504/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050951557 CMS
United Therapeutics Corporation $490.0004/24/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970509 CMS
United Therapeutics Corporation $23.2504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050957281 CMS
United Therapeutics Corporation $34.0504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050963647 CMS
United Therapeutics Corporation $125.0004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050968913 CMS
United Therapeutics Corporation $292.6704/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970129 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.5004/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000430883 CMS
United Therapeutics Corporation $21.8403/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050955373 CMS
United Therapeutics Corporation $35.0003/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050963959 CMS
United Therapeutics Corporation $487.8003/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970489 CMS
United Therapeutics Corporation $19.1303/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050952459 CMS
Astellas Pharma US Inc $25.0603/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033955949 CMS
Actelion Pharmaceuticals US, Inc. $620.0003/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772151 CMS
United Therapeutics Corporation $16.2302/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050949627 CMS
Merck Sharp & Dohme LLC $2,092.5002/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048535367 CMS
Mallinckrodt Hospital Products Inc. $17.3802/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042895281 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $233.9101/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993425227 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $172.3901/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993425229 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $73.6601/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993425231 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $47.0001/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993425233 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $479.7101/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993425221 CMS
Actelion Pharmaceuticals US, Inc. $23.2801/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772155 CMS
Actelion Pharmaceuticals US, Inc. $42.4501/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772157 CMS
Actelion Pharmaceuticals US, Inc. $39.5401/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772159 CMS
Actelion Pharmaceuticals US, Inc. $289.9701/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772161 CMS
Actelion Pharmaceuticals US, Inc. $620.0001/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988772153 CMS
United Therapeutics Corporation $490.0001/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050970507 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $68,473.70 124
PY2020 $41,129.41 48
PY2021 $44,679.18 61
PY2022 $46,772.22 92
PY2023 $57,681.66 101
PY2024 $55,290.88 122
PY2025 $61,245.60 139

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,160.00 1
PY2025 Principal investigator $114,080.56 76
PY2024 Recipient $2,030.00 3
PY2024 Principal investigator $38,471.77 5
PY2023 Principal investigator $681,794.98 21
PY2022 Principal investigator $20,079.36 5
PY2021 Principal investigator $281,166.92 23
PY2020 Principal investigator $102,474.84 39
PY2019 Principal investigator $310,590.78 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

77 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,199.60 12/15/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799527
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740177
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740179
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,306.00 11/25/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799525
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,000.00 11/13/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799535
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740173
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740175
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 10/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740181
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740183
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 10/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740185
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 10/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740187
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740189
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $795.00 10/22/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799523
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,674.80 10/03/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799533
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740169
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740171
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $109.35 10/01/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799519
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,350.00 10/01/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799521
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740159
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740161
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,206.80 08/18/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799531
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,465.00 08/14/2025 Non-covered Recipient Entity
INOVA FAIRFAX HOSPITAL
A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1190306729
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740155
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740157
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,696.30 07/29/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220799529
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740163
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 07/28/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740165
Principal investigator 1 Boehringer Ingelheim International GmbH $1.50 07/28/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740167
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,252.16 07/11/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Department Of Neurology
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220811688
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740151
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740153
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740145
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740147
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740149
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,260.00 05/27/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799517
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,952.70 05/07/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799515
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14.00 05/02/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220810768
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740137
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740139
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740141
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740143
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 04/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740123
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 04/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740125
Recipient United Therapeutics Corporation $1,160.00 03/26/2025 Covered Recipient Physician PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380092
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740105
Principal investigator 1 Boehringer Ingelheim International GmbH $42.06 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740107
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740109
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740111
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740113
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740115
Principal investigator 1 Boehringer Ingelheim International GmbH $4.80 03/25/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740117
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,158.20 03/11/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799513
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740083
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740085
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740087
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740089
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740075
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740077
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740079
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740081
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740091
Principal investigator 1 Boehringer Ingelheim International GmbH $14.02 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740093
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740095
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740097
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740099
Principal investigator 1 Boehringer Ingelheim International GmbH $4.44 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740101
Principal investigator 1 Boehringer Ingelheim International GmbH $1.60 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740103
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740127
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740129
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740131
Principal investigator 1 Boehringer Ingelheim International GmbH $6.72 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740133
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 01/27/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220740135
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,685.50 01/21/2025 Covered Recipient Teaching Hospital
Inova Loudoun Hospital Center
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220799511
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740071
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740073
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740119
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
Inova Fairfax Medical Campus
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220740121